Latest thinking.

Explore our latest insights and perspectives in these life science resources, news articles, and events.

Topic

Content Type

Preparing for ASH 2023: Heme-oncology research &...

We’re sharing some spotlights to help support our clients and partners navigate ASH 2023.

Spotlight on antibody drug conjugates (ADCs)

ADCs continued to be a spotlight at ESMO 2023. The team shares its key value drivers and associated limitations.

Podcast on leveraging AI in Medical Affairs

We partnered with the Medical Affairs Professional Society (MAPS) to release a podcast on "Leveraging AI for Medical Affairs".

Promoting technical excellence in HEOR and market ac...

We shared micro-tutorials at ISPOR Europe on nine critical scientific and strategic topics related to HTA. Contact us to discuss more.

Medical Affairs: A catalyst for advancing digital th...

We analyze the significant hurdles digital therapeutics continues to face and how medical affairs can influence their advancement.

Launching a product in a competitive access landscap...

Putnam partnered with the client to understand the potential of the product for UC treatment to maximize its commercial impact.

Navigating the future of Medical Affairs: Insights f...

With the evolving healthcare landscape and influence of AI and other technological innovations, Medical Affairs finds itself at a crucial juncture.

KOL mapping: Rare disease stakeholder engagement

We identified key stakeholders in priority markets, mapped out potential roles and evidence generation capabilities of identified KOLs.

Medical affairs medical insights framework

We provided strategic recommendations to analyze and synthesize monthly observations and medical insights for a product.

Integrated medical evidence

We helped our client to understand what evidence is required to support vaccine technical committee approvals.

Navigating drug pricing and HTA trends in Japan̵...

To understand the dynamics of drug pricing and HTA is key to grasping the future of healthcare in Japan.

Lessons to optimize EMA regulatory success using sin...

We set out to understand the likelihood of regulatory approval of oncology-based single-arm trials by the European Medical Agency (EMA).

Load 12 more of 76

Get in touch.

Looking to get in touch with an expert or team member?

Tell us how we can help.

Get in touch

Centers of Excellence